NCT00227227CompletedNot Applicable
Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Wyeth is now a wholly owned subsidiary of Pfizer0 sites750 target enrollmentStarted: May 2004Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 750
Study Overview
Brief Summary
The purpose of this study is to investigate the incidence of adverse events for patients with AS treated with Enbrel in usual care settings.
Study Design
- Study Type
- Observational
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of ankylosing spondylitis
Exclusion Criteria
- •Contraindications according SmPC
Investigators
Similar Trials
Completed
Not Applicable
Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque PsoriasisPlaque PsoriasisNCT00227240Pfizer753
Unknown
Phase 2
Etanercept (Enbrel) in Ankylosing SpondylitisAnkylosing SpondylitisNCT01289743Charite University, Berlin, Germany24
Completed
Not Applicable
Study Evaluating The Use Of Etanercept In Patients With Ankylosing SpondylitisAnkylosing SpondylitisNCT00544557Pfizer1,715
Unknown
Phase 2
Etanercept (Enbrel) in Undifferentiated SpondyloarthritisSpondyloarthritisNCT01289730Charite University, Berlin, Germany8
Completed
Phase 2
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki DiseaseMucocutaneous Lymph Node SyndromeKawasaki DiseaseNCT00841789Michael Portman205